Project Grant R21ES035196
- This Project Grant award, funded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program, supports research investigating the effects of ultraviolet radiation (UVR) exposure on chromatin structure and gene expression in melanocytes, which are the origin of cutaneous malignant melanoma. The $156,250 award, granted to the University of Toledo Health Science Campus, aims to elucidate how the loss of the BRG1 chromatin remodeling...
- Federal Project Grant Award Summary Chapman University received a $610,415 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on June 23, 2025, with a completion date of May 31, 2030. This award supports the development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for melanoma treatment. The research focuses on designing, synthesizing, and evaluating novel nNOS inhibitors with improved...
- This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant to Icahn School of Medicine at Mount Sinai under the Cancer Biology Research program (CFDA 93.396) for research addressing epigenetic regulation of melanoma-associated fibroblast plasticity. The two-year project (August 1, 2025 – July 31, 2027) focuses on understanding how histone variant dysfunction, specifically the loss of MacroH2A, affects cancer-associated fibroblasts (CAFs) in the...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded the University of Massachusetts Medical School a Cooperative Agreement totaling $922,755 (awarded August 28, 2025; completion July 31, 2030) under the Cancer Biology Research program (CFDA 93.396) to investigate tRNA modification reprogramming and translational remodeling in cancer, specifically melanoma progression and metastasis. The research employs comprehensive molecular and analytical methodologies to catalogue...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $487,468 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, effective September 1, 2025 through August 31, 2030. This five-year research initiative focuses on understanding palmitoylation dynamics and their role in melanoma lung metastasis progression. The project investigates how the palmitoyl-transferase enzyme...
- This $805,901 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding the University of California, San Francisco (UCSF) to investigate the molecular basis of cutaneous melanomas in non-Caucasian patients. The 3-year research project aims to advance scientific understanding of melanoma pathogenesis in diverse patient populations and explore new potential therapeutic approaches. As a leading academic medical center,...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...
- This $999,960 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program supports the development of LNS8801, a small molecule therapeutic for cutaneous melanoma patients who cannot tolerate immunotherapy. The funding will enable Linnaeus Therapeutics Inc. to advance LNS8801 through human clinical trials, building on preclinical work that has demonstrated LNS8801's antitumor efficacy and safety profile. LNS8801 is an orally deliverable, small...
- This Project Grant from the Department of the Army Medical Command provides $663,465 to New York University School of Medicine for research titled "Early Determinants of Melanoma Metastasis." The award period is from July 15, 2021 through July 14, 2024. The funding supports the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research. Specifically, the grant will fund New York...
NOVEL ROLE OF MELANIN-CARBONYLS IN PROGRESSION OF NRAS MUTANT MELANOMA - WE DISCOVERED MELANIN-CHEMIEXCITATION (MECH) WHERE NITRIC OXIDE SYNTHASE (NOS) OXIDIZES MELANIN INTO MELANIN-CARBONYLS (MCS) THAT HAVE TRIPLET ENERGY EQUIVALENT TO A UV PHOTON. THE MCS GENERATE ~50% OF THE TOTAL CYCLOBUTANE PYRIMIDINE DIMERS (CPDS), UV SPECIFIC DNA ADDUCTS, IN COMPLETE ABSENCE OF UV. THE CHEMICAL EVENTS THAT CONSPIRE DURING AND AFTER MECH, AND SPECIFICALLY THE ROLE OF MCS REMAIN UNKNOWN IN MELANOMA. WE PROPOSE TO IDENTIFY AND CHARACTERIZE THE ROLE OF MELANIN-CARBONYL-DNA (MCD) AND MELANIN- CARBONYL-PROTEIN (MCP) ADDUCTS IN MELANOMA PROGRESSION AND RESISTANCE AGAINST CURRENT THERAPEUTIC APPROACHES. THE RATIONALE IS THAT NOS IS MOSTLY HYPERACTIVE, AND ASSOCIATED WITH POOR PROGNOSIS OF MELANOMA PATIENTS, AND THE ROLE OF PIGMENTATION IS STILL CONTROVERSIAL IN MELANOMA. WE HYPOTHESIZE THAT HIGH NOS INDUCES MECH, LEADING TO CHRONIC MC PRODUCTION WHICH DYSREGULATES MELANOCYTIC PHYSIOLOGY, AND PROMOTES MELANOMA PROGRESSION AND THERAPY RESISTANCE THROUGH "MCD AND MCP ADDUCTS" OR OTHER UNKNOWN MECHANISMS. THE HYPOTHESIS RELATES TO THREE UNIQUE ARMS IN MELANOMA. FIRST IS PIGMENTATION. MELANIN PROMOTES MELANOMA BY ACTIVATING HIF-1A. CONTRARILY, MELANIN'S PHYSICAL EXISTENCE INHIBITS METASTASIS THROUGH ELASTICITY MODULATIONS, BUT REMAINS TO BE TESTED STRINGENTLY. SECOND IS MECH WHICH IS PROPOSED TO BE A CENTRAL AXIS IN MELANOMA BIOLOGY THOUGH NEVER TESTED EXPERIMENTALLY. THIRD IS THE NOS ENZYME, HYPERACTIVE IN MELANOMA, CORRELATES STRONGLY WITH POOR PROGNOSIS, AND EXCLUSIVELY ASSOCIATED WITH MELANIN. INTEGRATING THESE THREE ARMS WITH THE MECHANISMS OPERATED BY MCD AND MCP ADDUCTS, WE WILL IDENTIFY A POSITIVE LOOP IN MELANOMA THAT IS STEERED BY NOS, MECH, AND MCS IN THE FOLLOWING TWO AIMS: IN AIM 1, WE HYPOTHESIZE THAT OWING TO HYPERACTIVE NOS, THE CHRONIC MC PRODUCTION LEADS MCD AND MCP ADDUCTS. LABELING THE CELLULAR MELANIN USING CLICK-CHEMISTRY- ANALOGS (CCA) OF MELANIN-MONOMERS (PROTOCOLS ESTABLISHED), WE WILL INDUCE MECH CHEMICALLY OR WITH UV AND PURIFY AND CHARACTERIZE CCA LABELED GENOMIC AND PROTEOMIC FRACTION USING HPLC-MS/MS. FOCUS WILL BE ON CPD HOTSPOTS IN THE GENOME AND LYSINE AND CYSTEINE RICH PROTEINS FROM PROLIFERATIVE MELANOMA SIGNALING SINCE -NH2 AND -SH GROUPS ARE PRIME TARGETS FOR CARBONYL ADDUCTION IN AIM 2, WE HYPOTHESIZE THAT MCD AND MCP ADDUCTS PROMOTE MELANOMA PROGRESSION AND THERAPY RESISTANCE. WE SENSITIZED PATIENT DERIVED MELANOMA CELLS TO TARGETED THERAPIES BY SCAVENGING CARBONYLS AND INHIBITING NOS. ANALYSES ACROSS MELANOCYTES, DYSPLASTIC NEVI, AND MELANOMA, AND THE SELF-ESTABLISHED PIGMENTED AND NON-PIGMENTED, PATIENT DERIVED MELANOMA CELLS WILL IDENTIFY PROBABLE MECHANISMS BEHIND THIS SENSITIZATION WHICH IN OUR PRELIMINARY OBSERVATIONS, WAS INDEPENDENT OF THE DRIVER MUTATIONS LIKE BRAF OR NRAS. AN INTEGRATED ANALYSIS OF AIM 1 AND 2 WILL IDENTIFY MC-MEDIATED, NON-CLASSICAL REGULATION OF MELANOMA PROGRESSION AND THERAPY RESISTANCE THAT COULD BE USED AS A NOVEL VULNERABILITY AGAINST MELANOMA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($437) | 11/21/25 | ||
| Not listed | $463.4k | 7/21/23 |